Key result
Plasma apelin-13 levels were significantly lower (91.8 vs 126.0 pg/mL) and VEGF levels were significantly higher (113.1 vs 81.8 pg/mL) in preterm infants with retinopathy of prematurity compared to matched controls.
Why the study?
Although clinical studies have analysed venous blood levels of VEGF and apelin-13 in retinopathy of prematurity, no definitive conclusions have been reached.
Do plasma apelin-13 and VEGF levels differ between preterm infants with and without retinopathy of prematurity?
Case-Control (n=66)
No
Do plasma apelin-13 and VEGF levels differ between preterm infants with and without retinopathy of prematurity?
Absolute Event Rate: 91.8% vs 126%
p-value: p=<0.001
Plasma apelin-13 and VEGF levels measured at 4-6 weeks of age are significantly altered in infants with retinopathy of prematurity and may serve as diagnostic biomarkers.
Altered apelin-13 and VEGF levels associate with ROP; leaves open biomarker utility pending prospective validation.
BACKGROUND: Although several clinical studies have analysed the relationship between the levels of vascular endothelial growth factor (VEGF) and apelin-13 in venous blood and retinopathy of prematurity (ROP), no definitive conclusions have been reached. This study aimed to investigate the relationship between apelin-13 levels and VEGF levels and ROP. METHODS: Differences in plasma apelin-13 and VEGF levels were analysed in two groups of infants born with birth weight < 1500 g and gestational age < 32 weeks at Peking University People' s Hospital. One group comprised infants diagnosed with ROP and the other group was a control group comprising infants without ROP. RESULTS: Apelin-13 levels were significantly lower in the ROP group than in the control group, while VEGF levels showed the opposite result (both P < 0.001). Infants with severe ROP had lower apelin-13 levels and higher VEGF levels than with mild ROP (both P < 0.05).The receiver operating characteristic curve for apelin-13 level as the indicator of ROP showed that a cut-off value of 119.6 pg/mL yielded a sensitivity of 84.8% and a specificity of 63.6%, while for VEGF level, the cut-off value of 84.3 pg/mL exhibited a sensitivity of 84.8% and a specificity of 66.7%. CONCLUSIONS: Plasma apelin-13 and VEGF levels at 4-6 weeks of age may play a role in assisting the diagnosis of ROP.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a case-control in Retinopathy of prematurity (n=66). Plasma apelin-13 and VEGF levels vs. Infants without retinopathy of prematurity was evaluated on Plasma apelin-13 levels (pg/mL) (p=<0.001). Plasma apelin-13 levels were significantly lower (91.8 vs 126.0 pg/mL) and VEGF levels were significantly higher (113.1 vs 81.8 pg/mL) in preterm infants with retinopathy of prematurity compared to matched controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: